Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04804553 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

Study acronym: PEAPOD
StatusRecruiting
PhasePhase 3
SponsorAmgen
Started2022-03-17
View on ClinicalTrials.gov ↗
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.

Amendment record

Amended 58 times since 2021-03-16; most recent filed 2026-08-05. The 50 most recent of 59 record versions are listed below. See every version on ClinicalTrials.gov ↗

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-08-05
Amendment Study Status, Contacts/Locations v58
2026-07-23
Amendment Study Status, Contacts/Locations v57
2026-04-17
Amendment Study Status, Contacts/Locations v56
2026-02-04
Amendment Study Status, Contacts/Locations v55
2026-01-21
Amendment Study Status, Contacts/Locations v54
2026-01-14
Amendment Study Status, Contacts/Locations v53
2025-11-26
Amendment Study Status v52
2025-10-15
Amendment Study Status, Contacts/Locations v51
2025-10-07
Amendment Study Status v50
2025-09-10
Amendment Study Status, Contacts/Locations v49
2025-06-05
Amendment Study Status, Eligibility v48
2025-02-25
Amendment Study Status v47
2025-01-29
Amendment Study Status, Contacts/Locations v46
2025-01-01
Amendment Study Status, Contacts/Locations v45
2024-12-11
Amendment Study Status, Contacts/Locations v44
2024-09-27
Amendment Study Status v43
2024-07-31
Amendment Study Status, Contacts/Locations v42
2024-07-24
Amendment Study Status, Contacts/Locations v41
2024-07-05
Amendment Study Status, Contacts/Locations v40
2024-06-19
Amendment Study Status, Contacts/Locations v39
2024-06-12
Amendment Study Status, Contacts/Locations v38
2024-05-29
Amendment Study Status, Contacts/Locations v37
2024-04-30
Amendment Study Status, Contacts/Locations v36
2024-02-28
Amendment Study Status, Contacts/Locations v35
2024-01-25
Amendment Study Status, Contacts/Locations v34
2023-12-06
Amendment Study Status, Contacts/Locations v33
2023-10-18
Amendment Study Status v32
2023-07-05
Amendment Study Status, Contacts/Locations v31
2023-06-07
Amendment Study Status, Contacts/Locations v30
2023-04-26
Amendment Study Status, Contacts/Locations v29
2023-03-08
Amendment Study Status, Contacts/Locations v28
2023-02-22
Amendment Study Status, Contacts/Locations v27
2023-02-08
Amendment Study Status, Contacts/Locations v26
2023-02-01
Amendment Study Status, Contacts/Locations v25
2023-01-19
Amendment Study Status, Study Design, Outcome Measures, Eligibility, Contacts/Locations v24
2022-12-07
Amendment Study Status, Contacts/Locations v23
2022-11-30
Amendment Study Status, Contacts/Locations v22
2022-11-23
Amendment Study Status, Contacts/Locations v21
2022-11-07
Amendment Study Status v20
2022-10-12
Amendment Study Status, Contacts/Locations v19
2022-10-05
Amendment Study Status, Contacts/Locations v18
2022-09-28
Amendment Study Status, Contacts/Locations v17
2022-09-01
Amendment Study Status, Contacts/Locations v16
2022-08-11
Amendment Study Status, Contacts/Locations v15
2022-07-06
Amendment Study Status, Contacts/Locations v14
2022-06-22
Amendment Study Status, Contacts/Locations v13
2022-05-11
Amendment Study Status, Contacts/Locations v12
2022-04-13
Amendment Study Status, Contacts/Locations v11
2022-03-23
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v10
2022-02-28
Amendment Study Status v9
Trial Details
NCT Number NCT04804553
Lead Sponsor Amgen
Conditions Active Juvenile Psoriatic Arthritis
Enrollment 60 participants
Start Date 2022-03-17
Primary Completion 2028-03-21 (estimated)
Study Completion 2028-12-29 (estimated)
Updated on ClinicalTrials.gov 2026-09-03